In rodent α-synucleinopathy models, promoting autophagy by expressing BECN1 [87,88], ATG7 [70], LAMP2A [89,90] or treatment with rapamycin [70] reduces α-synuclein levels and ameliorates pathological disease markers. Here, ATG7 is linked to synucleinopathy.